Sensitivity pattern of cefotaxime against common uropathogens in vitro in Dhaka, Bangladesh
- 4 Downloads
The most common nosocomial infection worldwide is urinary tract infection (UTI), which can be treated with various antimicrobial agents.
The aim of this study was to assess the efficacy of cefotaxime, a third-generation cephalosporin, against potential uropathogens.
This study was carried out by retrospective analysis of laboratory data routinely collected from the Microbiology Department of the Ibn Sina Diagnostic and Consultation Center, Dhaka, Bangladesh. We used conventional methods for urine culture and sensitivity, the disc diffusion method for susceptibility, and SPSS software for data analysis.
A total of 3765 urine samples were collected during the period July 2017 to June 2018, of which 346 (9.19%) were bacteriologically positive. Among isolated uropathogens, 97.9% were Gram-negative bacteria and 2.1% were Gram-positive bacteria (Staphylococcus aureus, Streptococcus and Enterococcus). A higher proportion of males than females were prone to UTIs in the ≤ 10 and > 60 years age groups, and a higher proportion of females than males were affected in all age groups between 10 and 60 years. Escherichia coli was the most predominant (83.8%) isolate, followed by Klebsiella spp. (5.8%). Most of the uropathogens were sensitive to cefotaxime in males. Approximately 49.3% of males and 41.6% of females were resistant to E. coli.
Cefotaxime is still considered to be effective against uropathogens but its use should only be reserved for complicated UTIs and should follow antibiotic guidelines in order to prevent the emergence of multidrug-resistant organisms.
The authors would like to gratefully acknowledge Ibn Sina Diagnostic Center, Badda, Dhaka, Bangladesh, for their whole-hearted support to this work.
All authors contributed equally to this work.
Compliance with ethical standards
Conflict of interest
Md. Jahangir Alam, Runa Asma, Sumi Shohela Chowdury and Md. Rahimgir declare no conflicts of interest.
This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors.
- 1.Alam MJ, Juliana FM, Rahimgir M, et al. Resistance pattern of ciprofloxacin against common uropathogens in selected area of Dhaka city, Bangladesh. IOSR JNHS. 2017;6(5):52–7.Google Scholar
- 2.Hossain N, Das B, Alam MJ, et al. Susceptibility pattern of nitrofurantoin against uropathogens in selected areas of Dhaka city, Bangladesh. IOSR JNHS. 2017;6(5):60–5.Google Scholar
- 3.Alam MJ, Mousumi SJ, Rana R, et al. Ceftriaxone resistance patterns of uropathogens isolated from urinary tract infection patients in selected areas of Dhaka city, Bangladesh. IOSR JNHS. 2017;6(5):28–34.Google Scholar
- 4.Asaduzzaman M, Shamim A, Mian MS, et al. Resistance pattern of cefixime against uropathogens causing urinary tract infection in selected areas of Dhaka city, Bangladesh. IJES. 2018;7(1):33–9.Google Scholar
- 5.Asaduzzaman M, Miah AA, Bhuiyan MJA, et al. Resistant pattern of nalidixic acid against uropathogens in selected areas of Dhaka city, Bangladesh. Eur J Biomed Pharm Sci. 2018;5(3):90–5.Google Scholar
- 6.Asaduzzaman M, Hasan MZ, Khatun M, et al. Resistance pattern of levofloxacin against uropathogens causing urinary tract infection in selected areas of Dhaka city. Bangladesh. J Biol Agri Healthc. 2018;8(4):74–81.Google Scholar
- 7.Asaduzzaman M, Baral K, Islam MM, et al. Susceptibility pattern of second line antibiotic colistin against gram negative bacteria causing urinary tract infection in selected areas Dhaka city, Bangladesh. Eur J Biomed Pharm Sci. 2018;5(3):874–9.Google Scholar
- 8.Asaduzzaman M, Ullah MM, Sayed MR, et al. Emergence of meropenem resistance in pathogens recovered from urine cultures in Bangladesh. IOSR JPBS. 2018;13(3):41–7.Google Scholar
- 9.Asaduzzaman M, Hasin Z, Kumar A, et al. Efficacy of amikacin antibiotic to uropathogens isolated from patients urine sample causing urinary tract infection in selected areas of Dhaka city, Bangladesh. Int J Curr Innov Adv Res. 2018;1(3):89–99.Google Scholar
- 10.AHFS DI Essentials. Cefotaxime sodium: drug monograph. Bethesda, MD: American Society of Health-System Pharmacists; 2018.Google Scholar
- 11.Hamilton RJ, editor. Tarascon pocket pharmacopoeia 2015 deluxe lab-coat edition. Burlington, MA: Jones & Bartlett Learning; 2015 (ISBN: 9781284057560).Google Scholar
- 12.Wilma JP. Shafers medical surgical nursing. 7th ed. New Delhi: B.I. Publications; 2002. p. 637–40.Google Scholar
- 13.Nwanze P, Nwaru LM, Oranusi S, et al. Urinary tract infection in Okada village: prevalence and antimicrobial susceptibility pattern. Sci Res Essays. 2007;2(4):112–6.Google Scholar
- 14.Ginsburg CM, McCracken GH Jr. Urinary tract infections in young infants. Pediatrics. 1982;69:409–12.Google Scholar
- 15.Costa LC, Belém LF, Silva PM, et al. Infecções urinárias em pacientes ambulatoriais: prevalência e perfil de resistência aos antimicrobianos. Rev Bras Anal Clin. 2010;42:175–80.Google Scholar